Special Issue

Hybrid Nanoplatforms for Theranostics Nanomedicine

Message from the Guest Editor

Nanomedicine, the therapeutic branch of nanotechnology, has reached next generation clinical advances, and many nanomedicine products have been approved for cancer and infectious disease therapies. Hybrid nanoplatforms are capable of performing additional therapeutic modality in cancer and infectious disease management. The therapeutic modalities include early detection of the diseased cells, disease diagnosis, drug loading and delivery, external and internal stimuli responsive drug delivery, therapy, and therapy monitoring. A number of hybrid nanoplatforms have been developed to fight cancer and deadly pathogens; these hybrid nanoplatform include organic nanostructures, polymers, liposomes, lipids, inorganic nanostructures, gold nanoparticles, magnetic materials, silica nanoparticles, silver nanoparticles, titanium dioxide nanoparticles, biomolecules, protein, DNA nanostructures, antimicrobial peptides, metallic nanoparticles, and antiviral hybrid platforms.

Guest Editor

Dr. Nanasaheb Thorat

Nuffield Department of Women's & Reproductive Health, Medical Science Division, University of Oxford, Oxford, UK

Deadline for manuscript submissions

closed (31 July 2021)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/54200

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).